Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001636050-19-000062
Filing Date
2019-07-16
Accepted
2019-07-16 17:01:13
Documents
8
Period of Report
2019-08-16
Effectiveness Date
2019-07-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A axovantjuly2019def14a.htm DEF 14A 420993
2 EXHIBIT 99 proxycard.htm EX-99 9686
3 proxycard1.jpg GRAPHIC 76852
4 proxycard001.jpg GRAPHIC 139905
5 proxycard2.jpg GRAPHIC 60674
6 proxycard002.jpg GRAPHIC 102868
7 signaturea01.jpg GRAPHIC 9377
8 signaturea02.jpg GRAPHIC 9377
  Complete submission text file 0001636050-19-000062.txt   960507
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-37418 | Film No.: 19957619
SIC: 2834 Pharmaceutical Preparations